Initial Clinical Trial Site for Ph 1 Trial of CER-1236 in AML Announced
Chris Ehrlich, CERo Therapeutics CEO added, “It is encouraging to conduct our trial at one of the most renowned cancer centers in the United States, which we believe is a validation of the scientific work performed to date with CER-1236. The assignment of clinical trial sites is an important milestone. We look forward to announcing enrollment and first dosing in the near term.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.